Innovative Research Foundation

---

Compared to monoclonal antibodies/recombinant proteins, the mRNA platform offers faster design and lower cost; multi-target combinations aim at 'regenerative brakes' for long-lasting and functional benefits.

•Monoclonals (Leqembi): slow amyloid toxicity but do not restore plasticity.

•Proposed mRNA vaccine: first AD immunotherapy to directly target neurite outgrowth inhibitors, shifting focus from “debris clearance” to endogenous regeneration.

•Multi-epitope, B-cell-focused construct engineered for safety.

•In silico optimization avoids autoreactive epitopes.

•Builds on validated MultiTEP and NOI vaccine precedents..

•Manufacturing cost projected <$100/dose (vs. >$26,000/year for monoclonals).

•Synthetic, cell-free production scalable to millions of doses within weeks.

•Compatible with decentralized, open manufacturing models for equitable access.